TY - JOUR
T1 - Novel therapeutic strategy for cancer and autoimmune conditions
T2 - Modulating cell metabolism and redox capacity
AU - Fan, Xing Xing
AU - Pan, Hu Dan
AU - Li, Ying
AU - Guo, Rui Jin
AU - Leung, Elaine Lai Han
AU - Liu, Liang
N1 - Publisher Copyright:
© 2018 The Author(s)
PY - 2018/11
Y1 - 2018/11
N2 - Dysregulation of cell metabolism and redox balance is implicated in the pathogenesis and progression of cancer and autoimmune diseases. Because the cell proliferation and apoptotic regulatory pathways are interconnected with metabolic and redox signalling pathways, the current mono-target treatment is ineffective, and multi-drug resistance remains common. Complex diseases are often implicated in a network-based context of pathology; therefore, a new holistic intervention approach is required to block multi-crosstalk in such complicated circumstances. The use of therapeutic agents isolated from herbs to holistically modulate metabolism and redox state has been shown to relieve carcinoma growth and the inflammatory response in autoimmune disorders. Multiple clinically applied or novel herbal chemicals with metabolic and redox modulatory capacity as well as low toxicity have recently been identified. Moreover, new metabolic targets and mechanisms of drug action have been discovered, leading to the exploration of new pathways for drug repositioning, clinical biomarker spectra, clinical treatment strategies and drug development. Taken together with multiple supporting examples, the modulation of cell metabolism and the redox capacity using herbal chemicals is emerging as a new, alternative strategy for the holistic treatment of cancer and autoimmune disorders. In the future, the development of new diagnostic tools based on the detection of metabolic and redox biomarkers, reformulation of optimized herbal compositions using artificial intelligence, and the combination of herbs with mono-targeting drugs will reveal new potential for clinical application.
AB - Dysregulation of cell metabolism and redox balance is implicated in the pathogenesis and progression of cancer and autoimmune diseases. Because the cell proliferation and apoptotic regulatory pathways are interconnected with metabolic and redox signalling pathways, the current mono-target treatment is ineffective, and multi-drug resistance remains common. Complex diseases are often implicated in a network-based context of pathology; therefore, a new holistic intervention approach is required to block multi-crosstalk in such complicated circumstances. The use of therapeutic agents isolated from herbs to holistically modulate metabolism and redox state has been shown to relieve carcinoma growth and the inflammatory response in autoimmune disorders. Multiple clinically applied or novel herbal chemicals with metabolic and redox modulatory capacity as well as low toxicity have recently been identified. Moreover, new metabolic targets and mechanisms of drug action have been discovered, leading to the exploration of new pathways for drug repositioning, clinical biomarker spectra, clinical treatment strategies and drug development. Taken together with multiple supporting examples, the modulation of cell metabolism and the redox capacity using herbal chemicals is emerging as a new, alternative strategy for the holistic treatment of cancer and autoimmune disorders. In the future, the development of new diagnostic tools based on the detection of metabolic and redox biomarkers, reformulation of optimized herbal compositions using artificial intelligence, and the combination of herbs with mono-targeting drugs will reveal new potential for clinical application.
KW - Autoimmune condition
KW - Cancer
KW - Cell metabolism
KW - Gut microbiome
KW - Herbal medicine
KW - Redox
UR - http://www.scopus.com/inward/record.url?scp=85049356575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049356575&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2018.06.010
DO - 10.1016/j.pharmthera.2018.06.010
M3 - Review article
C2 - 29953901
AN - SCOPUS:85049356575
SN - 0163-7258
VL - 191
SP - 148
EP - 161
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
ER -